DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval

DexCom Inc. (DXCM) recently announced the FDA clearance of its Stelo glucose biosensor, available over-the-counter to consumers without a prescription.The company’s latest Continuous Glucose Monitoring (CGM) sensor, G7, is currently available on prescription. As an alternative for people without insurance coverage for CGM, Stelo's approval for non-prescription use would further facilitate this population's access to cutting-edge CGM technology.Price PerformanceFor the past six months, DXCM’s shares have gai ...